ABSTRACT

Objective: Breast carcinomas positive for the estrogen receptor (ER+) but negative for the progesterone receptor (PR−) have unfavorable prognostic features and are resistant to tamoxifen therapy. The goal of this study was to highlight the significance of PR− breast carcinomas.

Methods: Therefore, 146 breast carcinomas comprising 87 ER+/PR+ and 59 ER+/PR− carcinomas were examined. These two groups were compared in terms of age; tumor type; tumor size; histologic grade; presence of an in situ component; lymphovascular and perineural invasion; and ER, PR, c-Erb B2, Ki-67, and epidermal growth factor receptor (EGFR) status.

Results: While the number of metastatic lymph node and related pN2+pN3 tumors were found to be significantly higher in the ER+/PR− group, the differences with respect to the tumor size, metastatic lymph node size, and frequency of lymphovascular invasion were nearly significant.

Conclusion: ER+/PR− tumors have an unfavorable prognosis and show a clinical behavior closer to triple negative ones, although classified as luminal tumors. Revealing the mechanisms causing these differences will enhance the success of breast cancer therapy.

Keywords: Breast carcinoma, estrogen receptor, progesterone receptor, luminal type, prognosis

Estrogen Receptor Positive/Progesterone Receptor Negative Breast Carcinomas: A Subgroup Deserves Particular Interest

Zühal GÜCİN1, Melin Öзgün GEÇER2, Nur BÜYÜKPINARBAŞILI3, Cavide SÖNMEZ1, Yeliz Emine ERSOY2, Mahmut MÜSLÜMANOĞLU1

1Department of Pathology, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey
2Clinic of Pathology, Kartal Lütfü Kırdar Research and Training Hospital, Istanbul, Turkey
3Department of General Surgery, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey

Introduction

Among breast carcinomas, invasive ductal carcinoma forms the largest group of histological types and luminal carcinoma forms the largest group of molecular types. As tumors form such a large group, they are not expected to display one type of biological behavior, and thus, it is quite normal that their responses to treatment differ. There must be some mechanisms that cause these differences. The discovery of these mechanisms will enable the development of new treatment options.

In the luminal group, breast carcinomas that are estrogen receptor positive/progesterone receptor negative (ER+/PR−) are resistant to tamoxifen, have a higher proliferative activity, and display more frequent and earlier recurrence. The purpose here is to demonstrate the poor prognostic features of ER+/PR− breast carcinomas, to draw attention to their importance as a separate subtype, and to provide a preliminary study that will form the basis for further studies.

Methods

In this study, a total of 146 breast carcinoma cases that were diagnosed in two different centers (104 and 42 cases, respectively) are discussed. After the patients' surgical samples were fixed for 24 h in 10% buffered formaldehyde, standard follow-up was performed. Eighty-seven cases were ER+/PR− and 59 of them were ER+/PR+. Using the patients’ pathology reports, features, such as the age of the patient, type and size of the tumor, histological grade, lymph node (LN) status, multifocality, presence of in situ components, lymphovascular invasion (LVI), and perineural invasion (PIN) were compared. ER (rabbit, SP1, Thermo Scientific), PR (rabbit, SP2, Thermo Scientific), and Ki-67 (rabbit, SP6 Biocare) scores and HER1 (EGFR) (rabbit, EP38Y, Thermo Scientific) and HER2 (c-erb B2) (Mouse e2-4001+3B5, Thermo Scientific) were immunohistochemically evaluated. Immunohistochemical analysis was automatically performed on a Ventana Benchmark XT (USA) device.

If the ER and PR scores were over 1%, this was considered as positive. For the HER2 (c-erb B2) status, if the immunohistochemical score was 3 and the score that was supported by in situ hybridization was 2, the results were considered positive.
Because there were no definite criteria on EGFR (HER1)-positive status, all cytoplasmic stainings were assessed. The HER1 and HER2 statuses were discussed both separately and in terms of their association. When the Ki-67 score was 15% or above, it was considered to be high.

Statistical analysis

Descriptive statistics were given as mean±standard deviation. Quantitative variables, such as age, tumor size/diameter, LN size/diameter, number of LNs, and number of metastases, were tested for normal distribution suitability via the Kolmogorov–Smirnov test. It was found that all the variables, except age, did not comply with a normal distribution. Age, which complied with a normal distribution, was compared using the t-test and other variables were compared using the Mann–Whitney U test. With their percentages given, two state properties, such as type of tumor, multifocality, LVI, PNI, presence of an in situ component, Ki-67, and EGFR, were assessed using a chi-square test and Fisher’s exact test.

Results

Eighty-seven (59.6%) patients who were included in the study were ER+/PR− and 59 (40.4%) of them were ER+/PR+. For the cases forming these two groups, when age status was assessed using the t-test and tumor size, number of metastases were evaluated using the Mann–Whitney U test. With their percentages given, two state properties, such as type of tumor, multifocality, LVI, PNI, presence of an in situ component, Ki-67, and EGFR, were assessed using a chi-square test and Fisher’s exact test.

Discussion

Estrogen and ER play key roles in normal breast development and the formation of breast cancer (1). Progestosterone is regulated by estrogen, and its synthesis requires estrogen and ER (1). ER and PR statuses are often correlated with each other. However, ER+/PR− tumors form up to 15%–25% of breast cancer cases (2, 3). Although these tumors are ER+, they are tamoxifen resistant, have higher proliferative activity, exhibit more genomic variability, and are a different group in terms of clinical and biological behavior (1, 2, 4-6). Following endocrine therapy, whereas for ER+/PR− tumors, the recurrence rate was 7.6%, for ER+/PR− tumors, the ratio was found to be 14.8% (1). In another study, whereas the development of relapses in PR− tumors occurred in approximately 112 months, for PR− tumors, this period decreased to 24 months (p=0.005) (7). In these tumors, their aggressive behavior is associated with their both being ER+ tumors and having a high growth factor signaling. Indeed, in this tumor subgroup, HER1 and HER2 are highly expressed (4).

Bae et al. (6), in their study involving 6980 breast carcinoma patients, determined that cases that are single-hormone positive and patients who are HER2 negative demonstrate prognostic features that are worse and similar to those of triple-negative tumors compared with the ER+/PR−/HER2−
ER+/PR− group, the rate of HER2 overexpression/amplification was 21%, in the ER+/PR+ group, it was 14% (8). In our study, the rate of overexpression of HER2 was 17.20% in the PR− group, whereas in the PR− group, this ratio was 28.60%. Furthermore, HER1 and HER2 levels are reported to be higher in recurrent tumors.

In these tumors, ER levels are low despite their ER+/PR− status (8). The underlying mechanism of this in these tumors is explained by the occurrence of elevated HER1 and HER2 levels with high levels of growth factor receptors and the presence of “cross-talk” in the signaling pathways initiated by ER. This interference in signaling also explains the tamoxifen resistance (8). In its classically known form, ER status is the basic determining element in endocrine therapy for breast cancer, and most of the ER− cases are already PR−. Only up to 3%–5% of tumors are ER+/PR−, and in these cases, PR is used as a marker that shows whether the patient can respond to endocrine therapy. Recently, contrary to earlier claims, it has been emphasized that progesterone is also a proliferative hormone and is involved in the early stages of breast carcinogenesis (9). The ER+/PR− group is a different subgroup, and although it is ER+, this group is particularly known to be non-responsive to tamoxifen. In these groups, low PR levels, increased growth factor signaling, and increased tumor aggressiveness are discussed (3, 10). The loss of PRs after being affected by treatment indicates a poor prognosis (7). HER1 (EGFR) expression is also associated with a poor prognosis. Although HER1 overexpression is associated with high tumor grade and ER− status, some studies have been performed that yielded different results associated with HER3 and HER4, which are the other members of this family, and with different combinations (11-13). Furthermore, in our study, although in ER+/PR− tumors, co-expression of HER1 and HER2 was high, no statistical significance was detected. TIP30 protein acts as an angiogenesis inhibitor (14, 15) and stimulates the production of p53. Further, p53 protein, which acts as a tumor suppressor, ensures genome stability and inhibits cancer growth. TIP30 may also regulate p53 protein by directly binding to it (16). Although TIP30 normally regulates EGFR–EGFR endocytic trafficking, in the case of TIP30 deletion, a decrease in EGFR degradation and a prolonged EGFR signal are observed (17). TIP30 deletion increases the population of breast stem cells and progenitor cells and induces susceptibility in the development of ER− luminal tumors (2, 15, 18). Some studies performed in recent years have emphasized the relationship between TIP30 and tumors of other organs. Where- as TIP30 expression is a good prognostic marker in pancreatic ductal adenocarcinoma, loss of TIP30 has been associated with LN metastasis and downregulation of E-cadherin (19). In lung adenocarcinomas, a relationship between a decrease in TIP30 expression with an increase in EGFR activity and increased nuclear localization and metastasis is indicated (14, 19). Because of these characteristics, TIP30 protein can be a molecular candidate for a targeted therapy.

**Conclusion**

In this study, PR− breast carcinomas were determined to be larger in size, usually higher grade, with more frequent LN metastases, larger in diameter, and exhibiting a greater number of LN involvements. LVI was more common and the Ki-67 score was much higher. Both separately and together, overexpression of HER1 and HER2 occurs more frequently. In this study, the number of LN metastases, which was one of the parameters mentioned above, and accordingly the incidence of pN2 and pN3 tumors were significantly higher in the PR− group. The size of LN metastases, tumor diameter, and frequency of LVI were found to be nearly significantly different.

With these features, ER+/PR− tumors seem to deserve more special attention and require to be investigated from various aspects. In this group of breast cancers, there may be more than one mechanism that determines aggressive behavior. Besides growth factor receptors (HER1–4) and, among these, apart from TIP30 deletion, which is associated with HER1 (EGFR), these mechanisms might be associated with protein expression that provides a relationship with tumor stroma. Revealing these similar mechanisms will help us to understand why these tumors do not respond well to endocrine therapy and to develop new targeted treatment strategies.

**Ethics Committee Approval:** Due to the retrospective nature of this study, ethics committee approval was waived.

**Informed Consent:** Due to the retrospective nature of this study, informed consent was waived.

**Peer-review:** Externally peer-reviewed.


**Conflict of Interest:** The authors declared no conflict of interest.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**


